Trial Profile
Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs HS 10241 (Primary) ; Rivoceranib
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
- 06 Sep 2017 Status changed from not yet recruiting to recruiting.
- 14 Aug 2017 New trial record